Navigation Links
Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease
Date:4/1/2009

NEW YORK, April 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced that it would make up to $6.5 million in total funding available under three Critical Challenges research programs designed to accelerate solutions to some of the most difficult hurdles standing in the way of breakthrough therapeutics for PD.

The Critical Challenges funding opportunities focus research efforts on key priority areas in Parkinson's disease drug development. Priority challenges are chosen based on their relevance for addressing broader Foundation goals: define Parkinson's disease and its progression, alter the disease course and reduce its symptoms. The first 2009 Challenges are:

  • Clinicopathological Correlations of Parkinson's Disease will drive projects to understand the clinicopathological correlates of Parkinson's disease using extensive clinical data and postmortem tissue from normal control, PD and related disease subjects. Applicants will collaborate with the Arizona Parkinson's Disease Consortium, an existing MJFF grantee that has developed an exceptional bank of well-characterized postmortem tissue and associated clinical data.
  • Understanding LRRK2 Biology seeks proposals with potential to alter disease course by increasing understanding of the role of the gene LRRK2 in Parkinson's disease and developing essential tools to facilitate and accelerate research and therapeutic development efforts around this promising new therapeutic target. Ideal proposals will work to shed light on critical questions surrounding LRRK2, such as how LRRK2 pathogenic mutations directly lead to in vivo functional and pathological outcomes, and which cellular pathways LRRK2 normally and/or abnormally functions in.
  • Postural Instability and Gait Disorders will drive efforts to better treat PD symptoms by clarifying the pathophysiology and biological correlates of posture and gait dysfunction, which patients report to be one of the most debilitating aspects of living with PD, and which is not well-managed by currently available therapies.

"Through the Critical Challenges programs, MJFF targets research that we believe to have critical relevance to the entire field," said Katie Hood, CEO. "Our in-house research staff, in consultation with the Foundation's scientific advisors, designs each Challenge to address a specific priority area where our funding and expertise can make the greatest difference in speeding scientific developments toward the clinic and patients."

Critical Challenges complement the Foundation's annually recurring Pipeline Programs, which do not identify a specific research priority area to be pursued, but instead provide opportunities for projects at various stages of development to be funded, ensuring that new ideas continue flowing into Parkinson's research. Last November, MJFF announced $11 million in 2009 Pipeline Program funding.

Abbreviated information on the 2009 Critical Challenges follows. Full details are available at www.michaeljfox.org/research.cfm.

Clinicopathological Correlations of Parkinson's Disease 2009

Total available funding: $1.5 million

Deadline: 6 p.m. ET, Tuesday, May 19, 2009

Funding Anticipated: December 2009

Postural Instability and Gait Disturbances 2009

Total available funding: $2 million

Deadline: 6 p.m. ET, Friday, June 5, 2009

Funding Anticipated: December 2009

Understanding LRRK2 Biology 2009

Total available funding: $3 million

Deadline: 6 p.m. ET, Monday, June 1, 2009

Funding Anticipated: December 2009

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):